CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 37 enrolled
Drug / intervention
darunavir with ritonavir and fixed-dose viread+emtricitabine dailydrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01869634
NCT01869634Phase 4Completed
CompareCT.gov

Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART

University of California, Davis·interventional·Posted Jun 5, 2013·Updated Mar 4, 2020

In Brief

A Phase 4 clinical trial evaluating darunavir with ritonavir and fixed-dose viread+emtricitabine daily for Human Immunodeficiency Virus Infection. Completed, enrolled 37 participants across 1 site.

Detailed Summary

Potent HIV suppression with Darunavir-based antiretroviral therapy (ART) will lead to repopulation of gastrointestinal-associated lymphoid tissue (GALT) cluster of differentiation (CD)4+ T-cell populations, normalization of systemic immune activation, and improved HIV-associated cardiovascular disease (CVD) risk.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus Infection
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 5, 2013
Enrollment StartJun 1, 2013
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 13.1 years ago

Interventions

darunavir with ritonavir and fixed-dose viread+emtricitabine dailydrug